One Technology Place
About EMD Serono
At the EMD Group, around 40,000 people in more than 60 countries develop pharmaceutical and chemical innovations. In 2010 the company generated total revenues of EUR 9.3 billion. It is the world’s oldest pharmaceutical and chemical company with roots dating back to 1668. In 1917 the U.S. subsidiary Merck & Co. was expropriated and has been an independent company ever since.
From the start of industrial production in 1827, to initial research on liquid crystals more than 100 years ago, up to our entry into targeted cancer therapy with the launch of Erbitux®, many milestones in our history provide strong evidence of the pioneering spirit of the people at EMD. From innovative drugs to treat multiple sclerosis, cold remedies to new technologies for energy-efficient light sources our pioneering spirit in research and our experience enable us to develop products that improve quality of life.
Since going public in 1995, the company’s operating activities are under the umbrella of Merck KGaA Darmstadt, Germany.
Do you want to continue to experiment, analyze and break new ground? Welcome to EMD. When it comes to innovations, you will find us in the front ranks. And the breadth of our ceative research is far-reaching: from medicines, through opportunities in bio-research and bio-production, all the way to liquid crystals for LCDs. Enough latitude, in other words, to make your passion a true calling. Bring us entrepreneurial flair, plenty of team spirit and a total commitment to delivering the best possible results for our customers, and you’ll go far. You’ll enjoy all the interest and exposure of working in multidisciplinary, international teams. Depending on your field of expertise, you may even have the chance to develop across business sectors and functions.
To find out where you could go in an organization that’s part of Merck KGaA, Darmstadt, Germany, a global force in chemicals and pharmaceuticals with operations in more than countries and revenues of €9.3 billion in 2010, please visit come2emd.com.
EMD Group is an Equal Opportunity Employer.
EMD Serono is the largest division of the EMD Group and discovers, develops, manufactures and commercializes innovative prescription drugs and therapies for high unmet medical needs. The focus lies in specialist therapeutic areas such as oncology, multiple sclerosis and infertility. Through their targeted effect, these medicines help patients to live a longer and better life. Many consumers around the world trust a wide range of well-known brands that EMD develops, manufactures and markets for the OTC (over-thecounter) pharmaceutical sector.
Our broad range of specialty chemicals are used in technologically sophisticated applications ranging from liquid crystal, to effect pigments and cosmetic ingredients. The EMD Group is the global leader in the liquid crystals market. Liquid crystals are used throughout the world, in LCD TVs, monitors, tablet computers, notebooks, mobile phones, and digital cameras. In addition to the display materials business, the Performance Materials division focuses on materials for energy-saving lighting using LEDs (light-emitting diodes) and OLEDs (organic LEDs). Pigments for the plastics, printing and coatings industries as well as for cosmetic applications are an important part of the Performance Materials portfolio. Moreover, the division is the market leader for pearl-luster effect pigments.
With the EMD Millipore division, the EMD Group is a leading life science company, which offers products, applications and solutions for protein research and cell biology as well as for the manufacture of chemical-based and biopharmaceutical drugs. The portfolio comprises products for life science research such as assays, biomarkers and targeted solutions, as well as bioprocessing, lab water purification and filtration. Additionally, the division supplies specialty chemicals mainly to regulated markets, for example the pharmaceutical, cosmetics and food industries. Analytical and scientific laboratories use the reagents and test kits supplied by the division. The EMD Millipore portfolio comprises more than 40,000 products and processes.
Thank you in advance! I am looking forward to hearing from you.
83 articles with EMD Serono
EMD Serono Advances Oncology Portfolio and Pipeline with New and Long-term Data in Multiple Cancers at ESMO 2020
New analyses from Phase III JAVELIN Bladder 100 study of BAVENCIO®* assess efficacy across subgroups, patient-reported outcomes and exploratory biomarkers in advanced urothelial cancer
EMD Serono Awards Grant to American Cancer Society to Deliver Global Evaluation Data for SOURCE Program
Grant to fund expansion of cancer NGO capacity building efforts globally
MS On My Mind initiative uncovers emotional and physical impact MS has among individuals through artwork showcased at CMSC Annual Meeting
FDA Approves BAVENCIO® (avelumab) Plus INLYTA® (axitinib) Combination for Patients with Advanced Renal Cell Carcinoma
EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany in the US and Canada, and Pfizer Inc. (NYSE: PFE) announced that the US Food and Drug Administration (FDA) has approved BAVENCIO® (avelumab) in combination with INLYTA® (axitinib) for the first-line treatment of patients with advanced renal cell carcinoma (RCC).
Positive Phase II Data Further Highlights Clinical Proof of Concept for Evobrutinib, First Oral Bruton's Tyrosine Kinase (BTK) Inhibitor to Report Positive Phase II Clinical Results in MS
EMD Serono announced new 48-week results of the double-blind, randomized, placebo-controlled, Phase II study of evobrutinib in patients with relapsing multiple sclerosis (RMS).
EMD Serono to Present New Data on Mavenclad®, Rebif® and the Investigational Therapy Evobrutinib at the AAN Annual Meeting 2019
20 abstracts will be presented during the AAN Annual Meeting 2019 to demonstrate EMD Serono's commitment and clinical development program in multiple sclerosis
The lynchpin to biotech and pharmaceutical drug development in the United States is arguably the greater Boston area, which includes the white hot square mile of talent and intellectual collaboration found in Kendall Square.
EMD Serono, a unit of Merck KGaA, Darmstadt, Germany, announced that the U.S. Food and Drug Administration (FDA) had approved Mavenclad (cladribine) for adults with relapsing-remitting multiple sclerosis (RRMS) and active secondary progressive disease (SPMS).
Scientific presentations on cladribine tablets include analysis on durability of NEDA (no evidence of disease activity) status and safety analysis with up to 10 years of follow-up data in some patients
FDA Accepts sBLA and Grants Priority Review for BAVENCIO® (avelumab) Plus INLYTA® (axitinib) for the Treatment of Advanced Renal Cell Carcinoma
EMD Serono announced that the US Food and Drug Administration has accepted for Priority Review the supplemental Biologics License Application for BAVENCIO® in combination with INLYTA®* for patients with advanced renal cell carcinoma.
Merck KGaA, Darmstadt, Germany and GlaxoSmithKline forged an agreement to develop an immunotherapy for difficult to treat cancers that could be worth up to $4 billion. Following the announcement, a subsidiary of Merck KGaA announced plans to expand its Billerica, Mass. R&D facility.
EMD Serono Launches Community-Based Program to Advance Understanding of the Impact of Multiple Sclerosis on Patients and Caregivers
MS On My Mind is part of the company's #MSInsideOut global campaign, aimed at providing a deeper understanding of MS around the world
EMD Serono and Can Do MS Deliver Educational Programs and Support Groups to Multiple Sclerosis Caregivers
Embracing Carers™ today announced a new collaboration with Can Do Multiple Sclerosis to fill the shortage of resources focused on the unique needs, concerns, and unmet challenges of MS Care Partners.
Following several clinical disappointments and declining stock prices over the past year, Celgene tapped Alise Reicin as its new head of the company’s global clinical development unit, with a focus on mid- to late-stage therapeutics.
EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada, today announced the publication of results from a global Company-sponsored multiple sclerosis (MS) carer survey, as well as the premiere of the #MSInsideOut documentary, Seeing MS from the Inside Out,
Accelerated Cure Project Announces Collaboration with EMD Serono to Advance Patient-Focused Drug Development in Multiple Sclerosis
Accelerated Cure Project (ACP) for Multiple Sclerosis (MS) today announced it has entered into a ground-breaking collaboration with EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany in the U.S. and Canada, to capture and integrate the perspectives of people affected by MS into the design and implementation of clinical trials in MS.
IMMUTEP ENTERS INTO CLINICAL TRIAL COLLABORATION AND SUPPLY AGREEMENT WITH MERCK KGAA, DARMSTADT, GERMANY, AND PFIZER
Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”) is pleased to announce that it has entered into a clinical trial collaboration and supply agreement with Merck KGaA, Darmstadt, Germany and Pfizer.
9/4/2018Biopharm companies closed out August with a plethora of changes to executive and senior leadership positions. Let's take a look.
EMD Serono is shaking up its leadership. The biopharmaceutical arm of Germany-based Merck KGaA named Rehan Verjee as the new president of EMD Serono and global head of innovative medicine franchises at the parent company.
Synthorx, Inc. today announced the appointment of Joseph Leveque, M.D., as chief medical officer.